{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for beta root_modifications_structuralModifications_molecularFragment_refPname in root_modifications_structuralModifications_molecularFragment_refPname (approximate match)
Status:
US Previously Marketed
Source:
Xigris
(2001)
Source URL:
First approved in 2001
Source:
Xigris
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
First approved in 2016
Source:
BLA125582
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
First approved in 2015
Source:
BLA125426
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Alprolix by Bioverativ Canada Inc [Canada]
Source URL:
First approved in 2014
Source:
BLA125444
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Octaplex by Octapharma Pharmazeutika Produktionsges M B H [Canada]
Source URL:
First approved in 2013
Source:
BLA125421
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
First approved in 2013
Source:
BLA125421
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
First approved in 1999
Source:
BLA103665
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT00370877: Phase 4 Interventional Completed Postpartum Hemorrhage
(2007)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
NUCLEIC ACID